{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=31&state=California",
    "query": {
      "state": "California",
      "city": "Duarte",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 3059,
    "total_pages": 306,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=32&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Duarte&page=30&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T00:45:15.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03808922",
      "title": "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lower Respiratory Tract Infection",
        "Parainfluenza",
        "Immunocompromised",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "DAS181",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "DAS181 COVID-19",
          "type": "DRUG"
        },
        {
          "name": "DAS181 OL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 274,
      "start_date": "2019-05-23",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 23,
      "location_summary": "Duarte, California • Sacramento, California • Chicago, Illinois + 17 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03808922"
    },
    {
      "nct_id": "NCT04858256",
      "title": "Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-Cell Neoplasm",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-03-29",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04858256"
    },
    {
      "nct_id": "NCT01941056",
      "title": "Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection",
        "Healthy, no Evidence of Disease"
      ],
      "interventions": [
        {
          "name": "multi-CMV epitope modified vaccinia Ankara vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-01-05",
      "completion_date": "2017-07-28",
      "has_results": false,
      "last_update_posted_date": "2017-08-02",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01941056"
    },
    {
      "nct_id": "NCT06498973",
      "title": "Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Tagraxofusp-erzs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2025-01-28",
      "completion_date": "2027-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06498973"
    },
    {
      "nct_id": "NCT03904069",
      "title": "Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "AMG 553",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-03-13",
      "completion_date": "2030-08-07",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Palo Alto, California • Houston, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03904069"
    },
    {
      "nct_id": "NCT00003593",
      "title": "Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "asparaginase",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "therapeutic hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "thioguanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 254,
      "start_date": "1999-06",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-27",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 209,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003593"
    },
    {
      "nct_id": "NCT04416984",
      "title": "Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "ALLO-501A",
          "type": "GENETIC"
        },
        {
          "name": "ALLO-647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allogene Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2020-05-21",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04416984"
    },
    {
      "nct_id": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CML"
      ],
      "interventions": [
        {
          "name": "nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2013-08-12",
      "completion_date": "2018-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744665"
    },
    {
      "nct_id": "NCT07053436",
      "title": "Horizon Two: HR NDMM (MMRC-100)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk Newly Diagnosed Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bispecific Monoclonal Antibody and Triplet Therapy",
          "type": "DRUG"
        },
        {
          "name": "Monoclonal Antibody with Stem Cell Transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multiple Myeloma Research Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2026-04-30",
      "completion_date": "2035-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053436"
    },
    {
      "nct_id": "NCT04172532",
      "title": "Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Adenocarcinoma",
        "Stage III Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Peposertib",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2021-01-11",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-22T00:45:15.667Z",
      "location_count": 44,
      "location_summary": "Duarte, California • Irvine, California • Orange, California + 35 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172532"
    }
  ]
}